Siteman Cancer Center shared a post on X:
“AACR26: WashU Medicine radiation oncologist Carl DeSelm, MD, PhD, shares insights into tumor-reactive T cells during his AACR presentation, ‘A novel, first in class chimeric antigen receptor dendritic cell platform driving broad and durable antitumor immunity in solid tumors.'”
Other articles about Siteman Cancer Center and AACR on OncoDaily.